Premium
Tolerability and pharmacokinetics of remoxipride after intramuscular administration
Author(s) -
Kahn J.P.,
Yisak W.,
Albaret C.,
Nilsson L.,
ZaarHedin A.,
Laxenaire M.
Publication year - 1990
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1990.tb05287.x
Subject(s) - pharmacokinetics , tolerability , steady state (chemistry) , wilcoxon signed rank test , reproducibility , plasma concentration , medicine , pharmacology , chemistry , adverse effect , mann–whitney u test , chromatography
A study was undertaken in seven schizophrenic patients to evaluate the tolerability and examine the pharmacokinetics of intramuscularly administered remoxipride after a single 200 mg dose and at steady state following repeated doses of 200 mg twice daily for one week. Comparisons of AUC, t1/2 and t max using the Wilcoxon's signed rank test showed no significant difference between single dose and steady state indicating that the pharmacokinetics of intramuscular remoxipride were linear. The steady‐state C max was found to be significantly larger than that after single dose and the increase was accounted for by the predicted accumulation factor, assuming linear kinetics. Although the inter‐individual variability in plasma concentrations was large, the intra‐individual variability was low as shown by the reproducibility of the single‐dose and steady‐state plasma curves. Remoxipride, administered intramuscularly, was well tolerated.